{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:02:54Z","timestamp":1789448574705,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adenocarcinoma of the lower oesophagus and oesophagogastric junction (OGJ) is a malignancy of rising incidence in Western countries. Two multimodal strategies have dominated perioperative management: perioperative chemotherapy with the FLOT regimen (fluorouracil, leucovorin, oxaliplatin, docetaxel) and neoadjuvant chemoradiotherapy following the CROSS protocol (carboplatin\/paclitaxel with concurrent 41.4 Gy). The optimal approach has recently been evaluated in the ESOPEC phase III randomised controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To appraise and synthesise the current comparative evidence\u2014including randomised, observational, and real-world data\u2014on FLOT versus CROSS in resectable lower oesophageal adenocarcinoma (Siewert types I\u2013II).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted and reported in line with the PRISMA 2020 statement. PubMed\/MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were systematically searched (last run 30 June 2026), together with ClinicalTrials.gov. Thirteen reports from nine underlying studies were included. Risk of bias was assessed using RoB 2 (RCTs) and ROBINS-I (observational studies); certainty of evidence was appraised using GRADE. Synthesis followed the SWiM (Synthesis Without Meta-analysis) framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ESOPEC (n=438, median follow-up 55 months) is the only direct phase III RCT comparing FLOT with CROSS. Perioperative FLOT was associated with improved overall survival (median OS 66 vs. 37 months; HR 0.70, 95% CI 0.53\u20130.92; p=0.012) and progression-free survival (HR 0.66, 95% CI 0.51\u20130.85; p=0.001). Distant recurrence was significantly reduced with FLOT (3-year cumulative incidence 31.5% vs. 47.2%; HR 0.59; p&amp;lt;0.001), whilst locoregional control was equivalent (HR 1.00; p=0.99). The Neo-AEGIS trial (n=377) did not demonstrate a survival difference between CROSS and perioperative chemotherapy (3-year OS 57% vs. 55%; HR 1.03; p=0.82), but used a heterogeneous chemotherapy backbone. A propensity-matched retrospective cohort (n=222, 111\/arm) and the Dutch real-world CROSS cohort (n=4,765; median OS 33.7 months) provide context. GRADE certainty for the OS benefit is rated moderate. Patient-reported outcomes from ESOPEC are available as conference abstracts (EORTC QLQ-C30, QLQ-OES18 and CIPN20).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ESOPEC provides the strongest available evidence supporting perioperative FLOT over CROSS; however, because this conclusion is based primarily on a single open-label phase III trial, the evidence supports that FLOT is likely, rather than definitively, superior to CROSS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1887422","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:26:44Z","timestamp":1789446404000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative FLOT chemotherapy versus neoadjuvant chemoradiotherapy (CROSS protocol) in locally advanced adenocarcinoma of the lower oesophagus and oesophagogastric junction (Siewert types I\u2013II): systematic review and narrative synthesis (SWiM)"],"prefix":"10.3389","volume":"16","author":[{"given":"Zied","family":"Hadrich","sequence":"first","affiliation":[{"name":"Department of General Surgery, Mongi Slim University Hospital","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahir","family":"Omrani","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Mongi Slim University Hospital","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hajri","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Mongi Slim University Hospital","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Atallah","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Mongi Slim University Hospital","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiene","family":"Gabsi","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Mongi Slim University Hospital","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ElMontassar Belleh","family":"Zaafouri","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Mongi Slim University Hospital","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rached","family":"Bayar","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Mongi Slim University Hospital","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c6280","article-title":"Oesophageal cancer","volume":"390","author":"Lagergren","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji024","article-title":"The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence","volume":"97","author":"Pohl","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000168175.63782.9e","article-title":"Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma","volume":"29","author":"Liu","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1201\/9781003597162-33","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-esophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer (ESOPEC)","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannova","year":"2022","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2017.06.003","article-title":"Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study","volume":"43","author":"Favi","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.17_suppl.lba1","article-title":"Prospective randomised multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial)","volume":"42","author":"Hoeppner","year":"2024","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/jco.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomised controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00948","article-title":"Recurrence patterns of esophageal adenocarcinoma in the phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy","volume":"43","author":"Hoeppner","year":"2025","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"103011","DOI":"10.1016\/j.eclinm.2024.103067","article-title":"Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands","volume":"79","author":"van Laarhoven","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2026.44.16_suppl.105","article-title":"Patient reported outcomes (PRO) during and after multimodal treatment for resectable esophageal adenocarcinoma in the prospective, randomized, controlled, multicenter phase III ESOPEC trial","volume":"44","author":"Hoeppner","year":"2026","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doag052","article-title":"Real-world outcomes of FLOT versus Chemoradiotherapy for Esophageal, Type I and II Junctional Tumors: A Bi-Center International Study","volume":"39","author":"Alhayo","year":"2026","journal-title":"Dis Esophagus"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1887422\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:26:45Z","timestamp":1789446405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1887422\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1887422"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1887422","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1887422"}}